Specificity of acebutolol-induced antinuclear antibodies.
Treatment with the beta blocker acebutolol may trigger antinuclear antibody (ANA) production. We retrospectively studied 97 sera from 47 patients who developed ANA during acebutolol treatment. Anti-histone and anti-denatured (ss) DNA antibodies were found in 53% and 66% respectively of the sera tested. The activities of these two antibodies correlated well with the total ANA titer. Anti-native (ds) DNA were absent or present at low titer. This immunochemical pattern of acebutolol-induced ANA is similar to that reported for other drug-induced ANA. To date, the presence such isolated ANA is not known to expose patients to any particular risk other than exceptional and minor clinical manifestations of lupus which are rapidly reversible following therapy cessation.
D000070:Acebutolol / Q000009:adverse effects*; D000974:Antibodies, Antinuclear / Q000096:biosynthesis*; D000918:Antibody Specificity; D004247:DNA / Q000276:immunology; D004277:DNA, Single-Stranded / Q000276:immunology; D006657:Histones / Q000276:immunology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced
D000974:Antibodies, Antinuclear; D004277:DNA, Single-Stranded; D006657:Histones; D000070:Acebutolol; D004247:DNA